Comparison of methods for incorporating a radioiodinated residualizing cholesteryl ester analog into low density lipoprotein |
| |
| Affiliation: | 1. Department of Pharmacology, Ann Arbor, MI 48105, U.S.A.;2. Interdepartmental Program in Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109 U.S.A.;3. Parke-Davis Pharm. Res. Div., Warner-Lambert Co., Ann Arbor, MI 48105, U.S.A.;1. Leicester Diabetes Centre, Leicester General Hospital, University of Leicester, Leicester, UK;2. Diabetes Research Centre, College of Medicine, Biological Sciences and Psychology, University of Leicester, Leicester, UK;1. International Diabetes Federation, Chaussee de la Hulpe 166, Brussels, Belgium;2. Baker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne, Australia;3. Department of Preventive Medicine, Ajou University School of Medicine, 164 World Cup-ro, Suwon, South Korea;1. Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup, Jeonbuk 580-185, Republic of Korea;2. Department of Radiation Biotechnology and Applied Radioisotope Science, Korea University of Science and Technology, Daejeon 305-350, Republic of Korea |
| |
| Abstract: | Two different methods were evaluated for incorporating [125I]cholesteryl iopanoate ([125I]CI), a non-hydrolyzable cholesteryl ester analog, into LDL. The first procedure was an organic solvent delipidation-reconstitution procedure (R[125I-CI]LDL) while the second involved incubation of detergent (Tween-20)-solubilized [125I]CI with whole plasma (D[125I-CI]LDL). R[125I-CI]LDL behaved similar to native LDL in vitro, but was markedly different in vivo, apparently due to a heterogeneity in particle size. D[125I-CI]LDL, however, was metabolized normally both in vitro and in vivo. These results, combined with the residualizing nature of [125I]CI, demonstrate that D[125I-CI]LDL is appropriate for tracing LDL uptake in vivo. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
